Description
The Defense Health Agency (DHA) is conducting market research to determine whether a commercial solution can be provided to meet requirements for battlefield wound infection prevention and treatment: barrier combination product. This market research may also assist with the further development and/or refinement of the requirements. The DHA's Operational Medical Systems (OPMED) Warfighter Protection and Acute Care (WPAC) Project Management Office (PMO) has a requirement to develop, deliver, and field medical products that address battlefield wounds and subsequent bacterial and fungal infections. The Battlefield Wound Infection Prevention and Treatment (BWI P&T) program is using a Family of Systems (FoS) approach that aims to develop multiple medical materiel solutions that are most relevant for use in austere environments where medical products may be limited and evacuation may be prolonged.
• The barrier combination product must have the following minimum essential characteristics, as outlined in Attachment 3 - Minimum Essential Characteristics (MECS).
• The product is expected to be one of many components of the FoS that will provide novel solutions to the DoD and commercial market with respect to wound care and infection prevention.
• The product will likely be used across roles of care spanning the austere battlefield environment to hospital care settings.
• Interested parties shall submit the RFI response electronically by 2:00pm Eastern on January 20, 2026, via e-mail to Jeanette Collins at [email protected].
Attached files
Contact
Jeanette Collins